Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted

Date: November 1, 2011
Pages: 216
Price:
US$ 3,500.00
License [?]:
Publisher: GBI Research
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: ED34C6F3A34EN
Leaflet:

Download PDF Leaflet

Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted
Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted

Summary

GBI Research, the leading business intelligence provider, has released its latest research “Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted” which provides an insight into different endpoints that are used for the central nervous system (CNS) in clinical trials. The report examines different aspects under clinical trial endpoints in central nervous system disorders such as analysis on major marketed central nervous system drugs with an emphasis on safety and efficacy details. Phase II and Phase III clinical trial analysis for both completed and ongoing clinical trials, most promising central nervous system drugs with details on safety, efficacy and clinical trials, and terminated trial analysis. The company profiling highlights the central nervous system drugs of different companies.

The global CNS disease market is valued as $53.1 billion in 2010 that grew from $36.8 billion in 2002 with a CAGR of 4.7%. An increased geriatric population in many countries combined with increased life expectancy is expected to increase disease population of CNS disease. The product pipeline of CNS disease is promising with many novel molecules with disease modifying characteristics at various stages of development and is expected to fulfill the unmet needs in the CNS disease market. The product pipeline for multiple sclerosis has many orally administered novel molecules whereas for alzheimer’s disease, the product pipeline have novel molecules such as Bapineuzumab, Solanezumab, BMS-708163 that target the underlying causes of the disease and thus may offer significant benefits to the patients. The market for Schizophrenia and bipolar disorder is estimated to be driven by the anticipated launch of AZ-004 and other molecules such as Cariprazine, Zicronapine, RG1678 and Aripiprazole Depot injection. The continued uptake of non stimulants and expected launch of Kapvay and other pipeline molecules will have significant impact on market for ADHD. Although in upcoming years the market will witness patent expiries of major drugs, however this will be offset by the rapid uptake of new molecules, which will stabilize the market decline. The market is expected to grow with a CAGR of 1.4% from 2010 to 2017 to reach $58.6 billion in 2017.

This report details “Endpoints – Clinical Trials in Central nervous system Disorders”, highlighting the five major central nervous system disorders which are Alzheimer’s disease, Depression, Epilepsy, Parkinson’s disease and Schizophrenia. The classification of five major central nervous system diseases is done on the basis of, the number of pipeline molecules present in Phase III stage of development.

The term endpoint refers to an outcome or measure of a clinical trial. Endpoints can include all kinds of aspects, those related to the effectiveness of treatment and others. However, the endpoint selection must take into account the need to obtain the highest information of therapeutic interest with the least risk and discomfort for the individual. Also, the endpoints must be to the objective of the study and represent the most effective way to assess pharmacological response.

Scope
  • Data and analysis on the marketed products and analysis of their efficacy and safety details
  • Analysis of the five major Central nervous system diseases which include Alzheimer’s disease, depression, epilepsy, Parkinson’s disease and schizophrenia
  • Analysis of the Phase III and Phase II clinical trials in terms of percentage cases. Also analysis of terminated trials is included in this chapter. Only industry sponsored studies are included in the report.
  • Analysis on most promising molecules of five major central nervous system diseases with emphasis on their efficacy and safety details.
  • Company Profiling talks in detail about the companies, which are strong in the market.

Reasons to buy
  • Understand the trends in clinical trial endpoints used for central nervous system diseases
  • Build effective strategies to launch their pipeline products by identifying the right endpoints
  • Understanding and applying Surrogate endpoints and Clinical Biomarkers as endpoints for central nervous system diseases
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with increased efficiency and better safety profiles.
  • Develop key strategic initiatives by understanding the key focus areas of leading companies.
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 CLINICAL TRIAL DESIGN IN CENTRAL NERVOUS SYSTEM - OVERVIEW

2.1 Introduction
2.2 Types of Clinical Trial Outcomes
  2.2.1 Primary Outcomes
  2.2.2 Secondary Outcomes
2.3 GBI Research Report Guidance

3 ENDPOINTS - CLINICAL TRIALS IN CNS DISORDERS - TOP FIVE CNS DISORDERS AND THEIR PRODUCT PROFILING

3.1 Endpoints-Major Marketed Drugs of Top Five Central Nervous System Disorders and their Regulatory Approval
  3.1.1 Alzheimer’s disease
  3.1.2 Depression
  3.1.3 Epilepsy
  3.1.4 Parkinson’s disease
  3.1.5 Schizophrenia

4 ENDPOINTS - CLINICAL TRIALS IN CNS DISORDERS –MARKETED AND PIPELINE PRODUCT ASSESSMENTS

4.1 Alzheimer’s disease
  4.1.1 Primary Endpoints used in Alzheimer’s disease Clinical Trials
  4.1.2 Secondary Endpoints used in Alzheimer’s disease Clinical Trials
  4.1.3 Major Marketed Drugs-Safety and Efficacy Analysis
  4.1.4 Phase III Clinical Trial Analysis
  4.1.5 Most Promising Drugs’ Profiles
  4.1.6 Phase II Clinical Trial Analysis
  4.1.7 Terminated Trials Analysis
4.2 Depression
  4.2.1 Primary Endpoints used in Clinical Trials for Depression
  4.2.2 Secondary Endpoints used in Clinical Trials for Depression
  4.2.3 Major Marketed Drugs-Safety and Efficacy Analysis
  4.2.4 Phase III Clinical Trial Analysis
  4.2.5 Most Promising Drugs’ Profiles
  4.2.6 Phase II Clinical Trial Analysis
  4.2.7 Terminated Trials Analysis
4.3 Epilepsy
  4.3.1 Primary Endpoints used in Clinical Trials for Epilepsy
  4.3.2 Secondary Endpoints used in Clinical Trials for Epilepsy
  4.3.3 Major Marketed Drugs-Safety and Efficacy Analysis
  4.3.4 Phase III Clinical Trial Analysis
  4.3.5 Most Promising Drugs’ Profiles
  4.3.6 Phase II Clinical Trial Analysis
  4.3.7 Terminated Trials Analysis
4.4 Parkinson’s disease
  4.4.1 Primary Endpoints used in Clinical Trials for Parkinson’s disease
  4.4.2 Secondary Endpoints used in Clinical Trials Parkinson’s disease
  4.4.3 Major Marketed Drugs-Safety and Efficacy Analysis
  4.4.4 Phase III Clinical Trial Analysis
  4.4.5 Most Promising Drugs’ Profiles
  4.4.6 Phase II Clinical Trial Analysis
  4.4.7 Terminated Trials Analysis
4.5 Schizophrenia
  4.5.1 Primary Endpoints used in Clinical Trials for Schizophrenia
  4.5.2 Secondary Endpoints used in Clinical Trials for Schizophrenia
  4.5.3 Major Marketed Drugs-Safety and Efficacy Analysis
  4.5.4 Phase III Clinical Trial Analysis
  4.5.5 Most Promising Drugs’ Profiles
  4.5.6 Phase II Clinical Trial Analysis
  4.5.7 Terminated Trials Analysis

5 ENDPOINTS - CLINICAL TRIALS IN CNS DISORDERS - COMPANY PROFILES

5.1 Pfizer Inc.
  5.1.1 Company Profile
  5.1.2 Major Central Nervous System Disorders Products
5.2 GlaxoSmithKline Plc
  5.2.1 Company Profile
  5.2.2 Major Central Nervous System Disorders Products
5.3 AstraZeneca Plc
  5.3.1 Company Profile
  5.3.2 Major Central Nervous System Disorders Products
5.4 Sanofi
  5.4.1 Company Profile
  5.4.2 Major Central Nervous System Disorders Products
5.5 Johnson & Johnson
  5.5.1 Company Profile
  5.5.2 Major Central Nervous System Disorders Products
5.6 Eli Lilly and Company
  5.6.1 Company Profile
  5.6.2 Major Central Nervous System Disorders Products
5.7 Novartis AG
  5.7.1 Company Profile
  5.7.2 Major Central Nervous System Disorders Products
5.8 Abbott Laboratories
  5.8.1 Company Profile
  5.8.2 Major Central Nervous System Disorders Products
5.9 Forest Laboratories, Inc
  5.9.1 Company Profile
  5.9.2 Major Central Nervous System Disorders Products
5.10 Eisai Co., Ltd
  5.10.1 Company Profile
  5.10.2 Major Central Nervous System Disorders Products

6 ENDPOINTS - CLINICAL TRIALS IN CNS DISORDERS - APPENDIX

6.1 Market Definitions
6.2 Abbreviations
6.3 Research Methodology
  6.3.1 Clinical Trial Design Overview
  6.3.2 Marketed and Pipeline Products Assessment
  6.3.3 Company Profiles
6.4 Contact Us
6.5 Disclaimer
6.6 Sources

LIST OF TABLES

Table 1: Endpoints - Clinical Trials in CNS Disorders, Alzheimer’s disease, Endpoints for Major Marketed Drugs, Global,1990- 2010
Table 2: Endpoints - Clinical Trials in CNS Disorders, Depression, Endpoints for Major Marketed Drugs, Global,1990- 2010
Table 3: Endpoints - Clinical Trials in CNS Disorders, Epilepsy, Endpoints for Major Marketed Drugs, Global,1990- 2010
Table 4: Endpoints - Clinical Trials in CNS Disorders, Parkinson’s disease, Endpoints for Major Marketed Drugs, Global, 1990- 2010
Table 5: Endpoints - Clinical Trials in CNS Disorders, Parkinson’s disease, Endpoints for Major Marketed Drugs, Global, 1990- 2010
Table 6: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer’s Disease, Completed Phase III Trial Molecules, Secondary Endpoints, Global, 2000-2010
Table 7: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer’s Disease, Ongoing Phase III Trial Molecules, Secondary Endpoints, Global, 2000-2010
Table 8: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer’s Disease, Completed Phase II Trial Molecules, Secondary Endpoints, Global, 2000-2010
Table 9: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer’s Disease, Ongoing Phase II Trial Molecules, Secondary Endpoints, Global, 2000-2010
Table 10: Endpoints- Clinical Trials in Central Nervous System Disorders, List of Terminated Drugs for Alzheimer’s Disease
Table 11: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase III Trial Molecules, Primary Endpoints, Global, 2000-2010
Table 12: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Ongoing Phase III Trial Molecules, Primary Endpoints, Global, 2000-2010
Table 13: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Ongoing Phase III Trial Molecules, Secondary Endpoints, Global, 2000-2010
Table 14: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase II Trial Molecules, Primary Endpoints, Global, 2000-2010
Table 15: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Ongoing Phase II Trial Molecules, Primary Endpoints, Global, 2000-2010
Table 16: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Ongoing Phase II Trial Molecules, Secondary Endpoints, Global, 2000-2010
Table 17: Endpoints- Clinical Trials in Central Nervous System Disorders, List of Terminated Drugs for Depression
Table 18: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase III Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010
Table 19: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Ongoing Phase III Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010
Table 20: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase II Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010
Table 21: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Ongoing Phase II Trial Molecules, Primary Endpoints, Global, 2000-2010
Table 22: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Ongoing Phase II Trial Molecules, Secondary Endpoints, Global, 2000-2010
Table 23: Endpoints- Clinical Trials in Central Nervous System Disorders, List of Terminated Drugs for Epilepsy
Table 24: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson’s Disease, Completed Phase III Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010
Table 25: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson’s Disease, Ongoing Phase III Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010
Table 26: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson’s Disease, Completed Phase II Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010
Table 27: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson’s Disease, Ongoing Phase II Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010
Table 28: Endpoints- Clinical Trials in Central Nervous System Disorders, List of Terminated Drugs for Parkinson’s Disease
Table 29: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010
Table 30: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Ongoing Phase III Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010
Table 31: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase II Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010
Table 32: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Ongoing Phase II Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010
Table 33: Endpoints- Clinical Trials in Central Nervous System Disorders, List of Terminated Drugs for Schizophrenia
Table 34: Endpoints- Clinical Trials in Central Nervous Disorders, Pfizer Inc, Major Central Nervous Drugs, 2010
Table 35: Endpoints- Clinical Trials in Central Nervous Disorders, GlaxoSmithKline Plc, Major Central Nervous Drugs, 2010
Table 36: Endpoints- Clinical Trials in Central Nervous Disorders, AstraZeneca Plc, Major Central Nervous Drugs, 2010
Table 37: Endpoints- Clinical Trials in Central Nervous Disorders, Sanofi, Major Central Nervous Drugs, 2010
Table 38: Endpoints- Clinical Trials in Central Nervous Disorders, Johnson & Johnson, Major Central Nervous Drugs, 2010
Table 39: Endpoints- Clinical Trials in Central Nervous Disorders, Eli Lilly & Company, Major Central Nervous Drugs, 2010
Table 40: Endpoints- Clinical Trials in Central Nervous Disorders, Novartis AG, Major Central Nervous Drugs, 2010
Table 41: Endpoints- Clinical Trials in Central Nervous Disorders, Abbott Laboratories, Major Central Nervous Drugs, 2010
Table 42: Endpoints- Clinical Trials in Central Nervous Disorders, Forest Laboratories, Inc., Major Central Nervous Drugs, 2010
Table 43: Endpoints- Clinical Trials in Central Nervous Disorders, Eisai Co., Inc., Major Central Nervous Drugs, 2010

LIST OF FIGURES

Figure 1: Endpoints - Clinical Trials in CNS Disorders, Number of Pipeline products in Phase III Stage of Development, 2011
Figure 2: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer’s Disease, Completed Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
Figure 3: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer’s Disease, Completed Phase III Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010
Figure 4: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer’s Disease, Completed Phase III Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010
Figure 5: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer’s Disease, Completed Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
Figure 6: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer’s Disease, Completed Phase III Clinical Trials Classified Based on Rare Secondary Endpoints, Global, 2000-2010
Figure 7: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer’s Disease, Completed Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
Figure 8: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer’s Disease, Completed Phase III Clinical Trials Classified Based on Other Multiple Secondary Endpoints, Global, 2000-2010
Figure 9: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer’s Disease, Ongoing Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
Figure 10: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer’s Disease, Ongoing Phase III Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010
Figure 11: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer’s Disease, Ongoing Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
Figure 12: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer’s Disease, Ongoing Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
Figure 13: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer’s Disease, Ongoing Phase III Clinical Trials Classified Based on Other Multiple Secondary Endpoints, Global, 2000-2010
Figure 14: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer’s Disease, Completed Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
Figure 15: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer’s Disease, Completed Phase II Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010
Figure 16: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer’s Disease, Completed Phase II Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010
Figure 17: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer’s Disease, Completed Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
Figure 18: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer’s Disease, Completed Phase II Clinical Trials Classified Based on Other Secondary Endpoints, Global, 2000-2010
Figure 19: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer’s Disease, Completed Phase II Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
Figure 20: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer’s Disease, Completed Phase II Clinical Trials Classified Based on Other Multiple Secondary Endpoints, Global, 2000-2010
Figure 21: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer’s Disease, Ongoing Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
Figure 22: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer’s Disease, Ongoing Phase II Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010
Figure 23: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer’s Disease, Ongoing Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
Figure 24: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer’s Disease, Ongoing Phase II Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
Figure 25: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer’s Disease, Ongoing Phase II Clinical Trials Classified Based on Other Multiple Secondary Endpoints, Global, 2000-2010
Figure 26: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
Figure 27: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase III Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010
Figure 28: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase III Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010
Figure 29: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
Figure 30: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase III Clinical Trials Classified Based on Other Secondary Endpoints, Global, 2000-2010
Figure 31: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
Figure 32: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
Figure 33: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase II Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010
Figure 34: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase II Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010
Figure 35: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
Figure 36: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase II Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
Figure 37: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
Figure 38: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase III Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010
Figure 39: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
Figure 40: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase III Clinical Trials Classified Based on Other Secondary Endpoints, Global, 2000-2010
Figure 41: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
Figure 42: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Ongoing Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
Figure 43: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Ongoing Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
Figure 44: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Ongoing Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
Figure 45: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
Figure 46: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase II Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010
Figure 47: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
Figure 48: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase II Clinical Trials Classified Based on Other Secondary Endpoints, Global, 2000-2010
Figure 49: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase II Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
Figure 50: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Ongoing Phase II Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
Figure 51: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson’s Disease, Completed Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
Figure 52: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson’s Disease, Completed Phase III Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010
Figure 53: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson’s Disease, Completed Phase III Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010
Figure 54: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson’s Disease, Completed Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
Figure 55: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson’s Disease, Completed Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
Figure 56: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson’s Disease, Completed Phase III Clinical Trials Classified Based on Rare Multiple Secondary Endpoints, Global, 2000-2010
Figure 57: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson’s Disease, Ongoing Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
Figure 58: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson’s Disease, Ongoing Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
Figure 59: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson’s Disease, Ongoing Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
Figure 60: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson’s Disease, Completed Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
Figure 61: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson’s Disease, Completed Phase II Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010
Figure 62: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson’s Disease, Completed Phase II Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010
Figure 63: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson’s Disease, Completed Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
Figure 64: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson’s Disease, Completed Phase II Clinical Trials Classified Based on Other Secondary Endpoints, Global, 2000-2010
Figure 65: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson’s Disease, Completed Phase II Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
Figure 66: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson’s Disease, Completed Phase II Clinical Trials Classified Based on Other Multiple Secondary Endpoints, Global, 2000-2010
Figure 67: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson’s Disease, Ongoing Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
Figure 68: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson’s Disease, Ongoing Phase II Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010
Figure 69: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson’s Disease, Ongoing Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
Figure 70: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson’s Disease, Ongoing Phase II Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
Figure 71: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
Figure 72: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010
Figure 73: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010
Figure 74: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Other Multiple Primary Endpoints, Global, 2000-2010
Figure 75: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
Figure 76: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Other Secondary Endpoints, Global, 2000-2010
Figure 77: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
Figure 78: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Other Multiple Secondary Endpoints, Global, 2000-2010
Figure 79: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Ongoing Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
Figure 80: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Ongoing Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
Figure 81: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Ongoing Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
Figure 82: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
Figure 83: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase II Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010
Figure 84: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase II Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010
Figure 85: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
Figure 86: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Ongoing Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
Figure 87: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Ongoing Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010

COMPANIES MENTIONED

Pfizer Inc.
GlaxoSmithKline Plc
AstraZeneca Plc
Sanofi
Johnson & Johnson
Eli Lilly and Company
Novartis AG
Abbott Laboratories
Forest Laboratories, Inc
Eisai Co., Ltd

Ask Your Question

Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: